Free Trial

West Pharmaceutical Services, Inc. to Issue Quarterly Dividend of $0.21 (NYSE:WST)

West Pharmaceutical Services logo with Medical background

West Pharmaceutical Services, Inc. (NYSE:WST - Get Free Report) declared a quarterly dividend on Wednesday, January 29th,Wall Street Journal reports. Stockholders of record on Friday, February 7th will be given a dividend of 0.21 per share by the medical instruments supplier on Tuesday, February 11th. This represents a $0.84 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Friday, February 7th.

West Pharmaceutical Services has raised its dividend payment by an average of 5.4% per year over the last three years. West Pharmaceutical Services has a dividend payout ratio of 9.6% meaning its dividend is sufficiently covered by earnings. Research analysts expect West Pharmaceutical Services to earn $7.52 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 11.2%.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST traded down $3.22 during trading hours on Wednesday, reaching $340.07. The stock had a trading volume of 410,761 shares, compared to its average volume of 422,133. The firm has a market cap of $24.63 billion, a price-to-earnings ratio of 50.46, a PEG ratio of 18.59 and a beta of 1.00. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a fifty-two week low of $265.00 and a fifty-two week high of $413.70. The firm has a 50-day moving average of $329.87 and a 200-day moving average of $313.68.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of analyst reports. UBS Group raised West Pharmaceutical Services from a "neutral" rating to a "buy" rating and increased their target price for the stock from $350.00 to $390.00 in a research note on Thursday, December 12th. Citigroup began coverage on West Pharmaceutical Services in a report on Wednesday, January 8th. They set a "buy" rating and a $400.00 target price on the stock. Wolfe Research started coverage on West Pharmaceutical Services in a report on Friday, December 13th. They set a "peer perform" rating on the stock. Finally, Bank of America increased their target price on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $430.20.

Get Our Latest Stock Report on WST

West Pharmaceutical Services Company Profile

(Get Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Stories

Dividend History for West Pharmaceutical Services (NYSE:WST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in West Pharmaceutical Services Right Now?

Before you consider West Pharmaceutical Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.

While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How To Invest in Crypto as A Complete BEGINNER in 2025
3 AI Bargain Stocks to BUY NOW After the DeepSeek Crash
NVIDIA Stock Under Pressure: DeepSeek and the AI Tech War

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines